Therefore, targeting tumor angiogenesis is expected to be a new option for tumor suppression, and based on this, a variety of anti-angiogenic tumor therapeutics have been developed, such as bevacizumab, which specifically targets VEGF/VEGFR, and the multi-targeted agents sorafenib and sunitinib [7]. The gene discussed is KDR; the disease is neoplasm.